Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Up 15.4% in June

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 1,500 shares, a growth of 15.4% from the May 31st total of 1,300 shares. Based on an average daily volume of 300 shares, the short-interest ratio is currently 5.0 days.

Inhibitor Therapeutics Price Performance

Inhibitor Therapeutics stock remained flat at $0.08 during trading hours on Tuesday. The stock has a market cap of $13.61 million, a P/E ratio of -7.90 and a beta of -0.65. The business’s fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.08. Inhibitor Therapeutics has a one year low of $0.01 and a one year high of $0.30.

Inhibitor Therapeutics (OTCMKTS:INTI) last announced its earnings results on Friday, March 29th. The company reported ($0.01) EPS for the quarter.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.